Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jan 2019
Comparative StudyRegorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
To assess the efficacy and safety of regorafenib versus rechallenge chemotherapy in previously treated mCRC patients in third-line setting. ⋯ Rechallenge is still a valuable option against regorafenib in patients who achieved disease control in one of the first two lines of therapy. Even though mCRC patients treated with regorafenib benefited clinically from this treatment, we revealed that chemotherapy rechallenge compared to regorafenib was more effective in the third-line treatment for mCRC patients.